

CITATION REPORT

List of articles citing

Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease

DOI: 10.1111/liv.13739
Liver International, 2018, 38, 1793-1802.

Source: <https://exaly.com/paper-pdf/68927987/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
66	Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1109-1116	6.1	53
65	Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 849-866	4.2	24
64	Evolving Management Strategies for Nonalcoholic Fatty Liver Disease-Targeting Primary Care Physicians. <i>Diabetes Technology and Therapeutics</i> , 2019 , 21, 611-618	8.1	0
63	Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 361-374	4.2	44
62	Abstracts. <i>Liver International</i> , 2019 , 39, 2420-2468	7.9	
61	Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. <i>Journal of Investigative Medicine</i> , 2019 , 67, 303-311	2.9	34
60	Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019 , 43, 58-66	2.4	8
59	Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 710-718.e4	6.9	6
58	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 216-225.e5	6.9	46
57	Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 290-297	14.6	61
56	Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2020 , 54, 891-897	3	13
55	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2020 , 19, 674-690	3.1	24
54	Neue diagnostische Methoden für Patienten mit Diabetes und Fettleber. <i>Diabetologe</i> , 2020 , 16, 566-572	0.2	
53	The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). <i>Journal of Diabetes Research</i> , 2020 , 2020, 3920196	3.9	40
52	Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. <i>Life</i> , 2020 , 10,	3	4
51	Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future. <i>Seminars in Liver Disease</i> , 2020 , 40, 331-338	7.3	5
50	Non Alcoholic Fatty Liver Disease and Degree of Steatosis in Diabetic and Non- Diabetic patients. <i>Obesity Medicine</i> , 2020 , 19, 100243	2.6	2

49	Advances in non-invasive assessment of hepatic fibrosis. <i>Gut</i> , 2020 , 69, 1343-1352	19.2	68
48	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , 2021 , 73, 2238-2250	11.2	7
47	Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. <i>Hepatology Communications</i> , 2021 , 5, 559-572	6	7
46	FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients. <i>Diabetology International</i> , 2021 , 12, 118-125	2.3	0
45	The Role of Transient Elastography in NAFLD. 2021 , 61-74		
44	Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1). <i>Digestive and Liver Disease</i> , 2021 , 53, 1451-1457	3.3	3
43	Diabetes Liver Fibrosis Score to Detect Advanced Fibrosis in Diabetics with Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
42	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. <i>Life</i> , 2021 , 11,	3	6
41	Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	2
40	Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021 , 9, 607-614	5.2	1
39	Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study. <i>Obesity Science and Practice</i> , 2021 , 7, 497-508	2.6	0
38	Effect of type 2 diabetic mellitus in the prognosis of acute-on-chronic liver failure patients in China. <i>World Journal of Gastroenterology</i> , 2021 , 27, 3372-3385	5.6	3
37	Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4360-e4371	5.6	1
36	Inhibitory effects of extract against hepatic injury in a diabetic rat model. <i>Food Science and Biotechnology</i> , 2021 , 30, 979-988	3	1
35	Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. <i>Clinical Therapeutics</i> , 2021 , 43, 1505-1522	3.5	0
34	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. <i>Journal of Hepatology</i> , 2021 , 75, 659-689	13.4	102
33	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. <i>Diabetes and Metabolism</i> , 2021 , 47, 101272	5.4	5
32	Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107978	3.2	1

31	Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 3474-3483	4.5	3
30	Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma. <i>Transplantation Direct</i> , 2020 , 6, e605	2.3	1
29	Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. <i>PLoS ONE</i> , 2020 , 15, e0241770	3.7	7
28	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020 , 26, 3928-3938	3.3	2
27	Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. <i>Current Hypertension Reviews</i> , 2021 , 17, 94-111	2.3	3
26	High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 519-525	14.6	36
25	Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies. <i>Saudi Journal of Gastroenterology</i> , 2021 ,	3	2
24	Integrative Proposal for the Use of Biomarkers in Clinical Practice Management of NAFLD/NASH. 2020 , 225-236		
23	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 ,	4.5	1
22	Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022 ,	2.1	0
21	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. <i>Digestive and Liver Disease</i> , 2021 ,	3.3	1
20	Advances in fibrosis biomarkers in nonalcoholic fatty liver disease.. <i>Advances in Clinical Chemistry</i> , 2022 , 106, 33-65	5.8	0
19	Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	6.7	2
18	Impact of type 2 diabetes on the accuracy of non-invasive tests of liver fibrosis with resulting clinical implications.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	3
17	Determination of "indeterminate score" measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia.. <i>World Journal of Hepatology</i> , 2021 , 13, 2150-2160	3.4	0
16	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. <i>Eating and Weight Disorders</i> , 2021 , 1	3.6	1
15	Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.. <i>BMC Health Services Research</i> , 2022 , 22, 487	2.9	0
14	Reduced and more appropriate referrals of patients with type 2 diabetes using liver stiffness measurement compared to FIB-4.. <i>Irish Journal of Medical Science</i> , 2022 , 1	1.9	

13	Letter: non-invasive prediction models to exclude cirrhosis in NAFLD [Not everyone fits the mould. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 , 56, 182-183	6.1	
12	Letter: non-invasive prediction models to exclude cirrhosis in NAFLD [Not everyone fits the mould. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 , 56, 180-181	6.1	0
11	Noninvasive Algorithms for the Case Finding of At-Risk Patients with NAFLD. <i>Seminars in Liver Disease</i> ,	7.3	0
10	An individualized cirrhosis screening strategy might be more cost-effective in the general population. <i>Journal of Hepatology</i> , 2022 ,	13.4	0
9	Impact of diabetes, obesity, and dyslipidemia on the risk of HCC in patients with chronic liver diseases.		1
8	Diagnostik: Fibrosescores. 2022 , 157-165		0
7	Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes. 2022 , 10, 2375		1
6	Geographical similarity and differences in the burden and genetic predisposition of NAFLD.		3
5	Accuracy of FIB-4 to Detect Elevated Liver Stiffness Measurements in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Referral Centers. 2022 , 23, 12489		3
4	Diabetes and cirrhosis: Current concepts on diagnosis and management. Publish Ahead of Print,		0
3	Estimates and trends of the global burden of NASH-related liver cancer attributable to high fasting plasma glucose in 1990-2019: analysis of data from the 2019 Global Burden of Disease Study. 2023 , 15,		0
2	Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.		0
1	Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. 2023 ,		0